RxDoctor Payments Data

John Campbell, MD

Infectious Disease · Greensboro, NCNPI 1326096819

Payments from drug & device makers

$1,292in general payments, 2019–2025

Across 37 payments — averaging $34.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$593
  • Viiv Healthcare Company$178
  • Gilead$173
  • Insmed, Inc.$144
  • Cipla USA Inc.$105
  • Johnson & Johnson$23
  • plus $76 from 5 others

What the payments were for

  • Travel & lodging$47837%
  • Food & beverage$81463%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,292 in reported general payments places this provider in the 65th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,442
Medicare patients
15
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala329$1,362,555
GenvoyaElviteg/Cob/Emtri/Tenof Alafen107$464,223
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf62$285,225
TriumeqAbacavir/Dolutegravir/Lamivudi71$273,740
TivicayDolutegravir Sodium89$208,284
DescovyEmtricitabine/Tenofov Alafenam75$164,991
PrezcobixDarunavir/Cobicistat42$102,605
OdefseyEmtricitab/Rilpiviri/Tenof Ala18$64,461
PrezistaDarunavir18$38,999
Darunavir23$36,946
IntelenceEtravirine12$18,567
NorvirRitonavir13$3,444
Rifampin16$2,121
Ethambutol Hcl28$1,431
ValacyclovirValacyclovir Hcl17$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$173$1,991,769511 claims
Viiv Healthcare CompanyTriumeq, Tivicay$178$482,024160 claims
Johnson & JohnsonPrezcobix$23$102,60542 claims
AbbVieNorvir$12$3,44413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →